Physician profile
Jeffrey S Fromowitz
NPI 1265449003
$660,446.51
in general payments reported to CMS, 2019-2025
51 companies · $89K in 2025
The $89K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $55K · 2021: $42K · 2022: $104K · 2023: $152K · 2024: $108K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $311K · Food and Beverage: $15K · Consulting Fee: $13K · Travel and Lodging: $9,944 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $310,791.00 |
| Food and Beverage | $15,319.35 |
| Consulting Fee | $13,061.74 |
| Travel and Lodging | $9,944.16 |
| Education | $295.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $154,348.64 | 2019-2025 | Aklief, Twyneo, Oracea |
| Amgen INC. | $116,434.62 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $100,414.79 | 2019-2025 | |
| Incyte Corporation | $55,487.91 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $52,313.62 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $43,052.20 | 2022-2024 | Vtama |
| Genzyme Corporation | $30,862.47 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25,516.22 | 2019-2025 | Siliq, Targretin, Jublia |
| Leo Pharma INC. | $19,406.68 | 2019-2025 | Adbry, Anzupgo |
| Almirall LLC | $16,315.37 | 2019-2025 | Seysara, Klisyri |
| Vyne Pharmaceuticals INC. | $15,761.37 | 2020-2021 | |
| Botanix Sb INC | $5,745.04 | 2025 | Sofdra |
| Sensus Healthcare, INC. | $4,667.18 | 2019-2021 | |
| Celgene Corporation | $3,114.91 | 2019 | |
| Sun Pharmaceutical Industries INC. | $2,827.52 | 2019-2025 | Blu-U, Odomzo, Winlevi |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Fromowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.